HK1051324A1 - Methods and compositions for modulating alpha adrenergic receptor activity. - Google Patents

Methods and compositions for modulating alpha adrenergic receptor activity.

Info

Publication number
HK1051324A1
HK1051324A1 HK03103605A HK03103605A HK1051324A1 HK 1051324 A1 HK1051324 A1 HK 1051324A1 HK 03103605 A HK03103605 A HK 03103605A HK 03103605 A HK03103605 A HK 03103605A HK 1051324 A1 HK1051324 A1 HK 1051324A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
adrenergic receptor
receptor activity
alpha adrenergic
Prior art date
Application number
HK03103605A
Other languages
English (en)
Inventor
Ken Chow
Daniel W Gil
Wenkui Ken Fang
Michael E Garst
Larry A Wheeler
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HK1051324A1 publication Critical patent/HK1051324A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
    • C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
HK03103605A 2000-04-13 2003-05-21 Methods and compositions for modulating alpha adrenergic receptor activity. HK1051324A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/548,410 US6313172B1 (en) 2000-04-13 2000-04-13 Methods and compositions for modulating alpha adrenergic receptor activity
PCT/US2001/011843 WO2001078703A2 (en) 2000-04-13 2001-04-11 Methods and compositions for modulating alpha adrenergic receptor activity

Publications (1)

Publication Number Publication Date
HK1051324A1 true HK1051324A1 (en) 2003-08-01

Family

ID=24188743

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103605A HK1051324A1 (en) 2000-04-13 2003-05-21 Methods and compositions for modulating alpha adrenergic receptor activity.

Country Status (12)

Country Link
US (1) US6313172B1 (xx)
EP (1) EP1280525B1 (xx)
JP (1) JP2003530430A (xx)
AT (1) ATE288747T1 (xx)
AU (2) AU2001253384B2 (xx)
CA (1) CA2406057C (xx)
DE (1) DE60108857T2 (xx)
ES (1) ES2233627T3 (xx)
HK (1) HK1051324A1 (xx)
NZ (1) NZ522027A (xx)
TW (1) TWI299662B (xx)
WO (1) WO2001078703A2 (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
US7335803B2 (en) 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US6534542B2 (en) * 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
EP1542719A4 (en) 2001-12-05 2006-06-21 Baylor College Medicine METHODS AND COMPOSITIONS FOR REGULATING OS FORMATION BY MODULATING THE SYMPATHETIC TONUS
ES2325360T3 (es) * 2002-02-13 2009-09-02 Vitreo-Retinal Technologies, Inc. Tratamiento de trastornos oftalmicos usando urea y derivados de urea.
US7323485B2 (en) 2002-05-21 2008-01-29 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7358269B2 (en) 2002-05-21 2008-04-15 Allergan, Inc. 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040096089A1 (en) * 2002-08-16 2004-05-20 David Borsook Non-invasive functional imaging of peripheral nervous system activation in humans and animals
CN100370988C (zh) * 2002-10-08 2008-02-27 阿勒根公司 (2-咪唑啉-2-基氨基)喹噁啉在制备治疗痴呆症和帕金森病的药物中的用途
ATE429216T1 (de) * 2002-10-08 2009-05-15 Allergan Inc Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20060293359A1 (en) * 2003-06-25 2006-12-28 Allergan, Inc. Methods and compositions for the treatment of diabetes
KR101292492B1 (ko) 2004-05-11 2013-08-01 이모셔널 브레인 비.브이. 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
JP2008514603A (ja) 2004-09-24 2008-05-08 アラーガン、インコーポレイテッド α２アドレナリン作動剤としての４−（ヘテロアリール−メチルおよび置換ヘテロアリール−メチル）−イミダゾール−２−チオン
JP2009500409A (ja) * 2005-06-29 2009-01-08 アラーガン、インコーポレイテッド 痛みを処置するためのα２アドレナリン作動剤
US7390829B2 (en) * 2005-06-29 2008-06-24 Allergan, Inc. Alpha-2 adrenergic agonists
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US7902247B2 (en) * 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
RU2016134989A (ru) * 2010-08-16 2018-12-11 Аллерган, Инк. Применение агонистов альфа-2в рецепторов для получения лекарственного средства и способы лечения (варианты)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562391A (en) * 1969-06-17 1971-02-09 American Cyanamid Co Method of suppressing inflammation in mammals
SU795462A3 (ru) 1975-03-14 1981-01-07 Эдьт Дьедьесерведьесети Дьяр (Фирма) Способ получени тиокарбамидныхпРОизВОдНыХ
US4460602A (en) * 1981-06-30 1984-07-17 The Procter & Gamble Company Urea derivatives
GB8715357D0 (en) * 1987-06-30 1987-08-05 Sandoz Inst For Medical Resear Organic compounds
US4988688A (en) * 1989-08-02 1991-01-29 Warner-Lambert Company 4-(N-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents
HU210683B (en) * 1990-06-18 1995-06-28 Sandoz Ag Process for producing n-benzyl-n1-(phenyl-alkyl)-thiourea derivatives and pharmaceutical compositions containing the same
US5212176A (en) 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity

Also Published As

Publication number Publication date
CA2406057A1 (en) 2001-10-25
US6313172B1 (en) 2001-11-06
EP1280525B1 (en) 2005-02-09
DE60108857T2 (de) 2005-12-29
ATE288747T1 (de) 2005-02-15
AU2001253384B2 (en) 2006-02-02
DE60108857D1 (de) 2005-03-17
WO2001078703A3 (en) 2002-03-21
AU5338401A (en) 2001-10-30
CA2406057C (en) 2009-08-04
EP1280525A2 (en) 2003-02-05
WO2001078703A2 (en) 2001-10-25
JP2003530430A (ja) 2003-10-14
NZ522027A (en) 2004-11-26
ES2233627T3 (es) 2005-06-16
TWI299662B (en) 2008-08-11

Similar Documents

Publication Publication Date Title
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
IL144948A0 (en) Electroactive pore
AU5624699A (en) Use of 5ht-6 antagonists
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
MY140767A (en) Compounds, methods and compositions
TR200100054T2 (tr) Paroksetin metansülfonat
EP1404863A4 (en) PIBS AS P53 PATH MODIFICATORS AND USE METHOD
MY151032A (en) Treatment of tnf? related disorders
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU2001253384A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
TR199902449T2 (xx) Farmakolojik etkin maddeler.
SE9802208D0 (sv) Novel compounds
MY137620A (en) Therapeutic treatment
AU2003252025A8 (en) Compounds, compositions, and methods
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
TR200200278T2 (tr) Kalsilitik bileşimler
SE9802209D0 (sv) Novel compounds
MX2007004461A (es) Composiciones farmaceuticas a base de antagonistas de nk2 para uso pediatrico.
CA2416879A1 (en) Methods of treating cancer and the pain associated therewith using endothelin antagonists
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
UA32314A (uk) Спосіб лікування некротичного панкреатиту

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110411